The present invention provides a method of treating a patient diagnosed with Myxoid/Round cell liposarcoma with an anti-GPC3 therapeutic agent. The present invention also relates to quantification of GPC3 expression in tissue samples of patients diagnosed with Myxoid/Round cell liposarcoma by an immunostaining assay and identification of GPC3 expression levels that correlate with selection of patients for administering the anti-GPC3 therapeutic agent.

The present invention provides an antibody against glypican-3 (GPC3) and application thereof, and the antibody comprises a single chain antibody and humanized antibody.

Optimized chimeric antigen receptors (CARs) targeting glypican-3 (GPC3) and having a 12-amino acid hinge region derived from human IgG4 are described. The optimized CARs also include a transmembrane domain from either CD8 or CD28, an intracellular co-stimulatory domain and an intracellular signaling domain. Immune cells or induced pluripotent stem cells expressing the optimized CARs can be used to treat GPC3-positive solid tumors.

The present disclosure generally relates to, inter alia, a class of chimeric switch receptors containing an endodomain of an IL-9 receptor, engineered to modulate transcriptional regulation in a ligand-dependent manner. The disclosure also provides compositions and methods useful for producing such receptors, nucleic acids encoding same, host cells genetically modified with the nucleic acids, as well as methods for modulating gene expression, modulating an activity of a cell, and/or for the treatment of various health conditions or diseases.

GPC3 T cell antigen coupler (TAC) polypeptides having (i) an antigen-binding domain that binds GPC3, (ii) an antigen-binding domain that binds a protein associated with a TCR complex, and (iii) a T cell receptor signaling domain polypeptide are provided.

The present disclosure generally relates to, inter alia, a class of chimeric switch receptors containing an endodomain of an IL-9 receptor, engineered to modulate transcriptional regulation in a ligand-dependent manner. The disclosure also provides compositions and methods useful for producing such receptors, nucleic acids encoding same, host cells genetically modified with the nucleic acids, as well as methods for modulating gene expression, modulating an activity of a cell, and/or for the treatment of various health conditions or diseases.

Provided herein are engineered receptors that include an extracellular domain (ECD) from a TGF- receptor, a transmembrane domain (TMD), and that lack amino acid residues for signaling and phosphorylation, where such receptors are involved in cytokine signaling, for modulating TGF- signaling, for methods of modulating TGF- signaling, and for treating cancer using chimeric antigen receptors.

This disclosure relates to compositions and methods for treating cancer using armored chimeric antigen receptor cells.

Compositions and methods for binding to target antigens. Compositions comprising variable heavy chain domains with binding specificity to CD70, GPC3, IL13Ralpha2 and Cadherin CDH17 antigens.

Disrupting convergence of lytic granules produced by cytotoxic lymphocytes allows non-directional degranulation, which improves and broadens killing efficiency of the cytotoxic cells in pathogenic environments such as when used for cancer therapy. Accordingly, methods of inducing multidirectional degranulation by cytotoxic effector cells in a tumor microenvironment, methods of treating a tumor, and related therapeutic composition are described.